Financhill
Buy
66

ZBH Quote, Financials, Valuation and Earnings

Last price:
$93.45
Seasonality move :
1.98%
Day range:
$93.15 - $94.86
52-week range:
$89.22 - $116.71
Dividend yield:
1.02%
P/E ratio:
20.85x
P/S ratio:
2.48x
P/B ratio:
1.50x
Volume:
1.5M
Avg. volume:
1.9M
1-year change:
-12.32%
Market cap:
$18.6B
Revenue:
$7.7B
EPS (TTM):
$4.52

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ZBH
Zimmer Biomet Holdings
$2.1B $1.98 5.85% 67.94% $108.44
ABT
Abbott Laboratories
$11.1B $1.26 6.75% 41.8% $142.55
EW
Edwards Lifesciences
$1.5B $0.62 8.9% -88.36% $81.79
STE
Steris PLC
$1.4B $2.27 6.5% 55.14% $264.88
SYK
Stryker
$5.9B $3.07 9.23% 43.28% $422.71
TMCI
Treace Medical Concepts
$47.1M -$0.29 5.9% -21.86% $10.02
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ZBH
Zimmer Biomet Holdings
$94.22 $108.44 $18.6B 20.85x $0.24 1.02% 2.48x
ABT
Abbott Laboratories
$131.74 $142.55 $229.2B 17.09x $0.59 1.76% 5.44x
EW
Edwards Lifesciences
$76.14 $81.79 $44.7B 10.88x $0.00 0% 8.18x
STE
Steris PLC
$227.62 $264.88 $22.4B 36.71x $0.57 1% 4.13x
SYK
Stryker
$390.87 $422.71 $149.4B 52.82x $0.84 0.85% 6.50x
TMCI
Treace Medical Concepts
$5.85 $10.02 $368M -- $0.00 0% 1.73x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ZBH
Zimmer Biomet Holdings
36.67% -0.270 32.03% 1.27x
ABT
Abbott Laboratories
21.34% 0.677 6.18% 1.27x
EW
Edwards Lifesciences
5.57% 0.165 1.4% 3.33x
STE
Steris PLC
23.64% 0.478 9.17% 1.19x
SYK
Stryker
44.5% 1.100 12.02% 0.80x
TMCI
Treace Medical Concepts
33.65% 3.653 10.12% 3.23x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ZBH
Zimmer Biomet Holdings
$1.4B $338.9M 4.85% 7.29% 15.46% $335.8M
ABT
Abbott Laboratories
$5.9B $1.7B 23.5% 31.31% 18.43% $933M
EW
Edwards Lifesciences
$1.1B $409.9M 43.97% 46.91% 29.02% $224.4M
STE
Steris PLC
$641.2M $279.6M 6.94% 9.5% 14.48% $189.9M
SYK
Stryker
$3.7B $872M 8.33% 14.2% 14.87% $127M
TMCI
Treace Medical Concepts
$41.9M -$15.6M -32% -47.17% -27.79% $655K

Zimmer Biomet Holdings vs. Competitors

  • Which has Higher Returns ZBH or ABT?

    Abbott Laboratories has a net margin of 9.53% compared to Zimmer Biomet Holdings's net margin of 12.79%. Zimmer Biomet Holdings's return on equity of 7.29% beat Abbott Laboratories's return on equity of 31.31%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZBH
    Zimmer Biomet Holdings
    71.2% $0.91 $19.6B
    ABT
    Abbott Laboratories
    56.86% $0.76 $62.3B
  • What do Analysts Say About ZBH or ABT?

    Zimmer Biomet Holdings has a consensus price target of $108.44, signalling upside risk potential of 15.09%. On the other hand Abbott Laboratories has an analysts' consensus of $142.55 which suggests that it could grow by 8.2%. Given that Zimmer Biomet Holdings has higher upside potential than Abbott Laboratories, analysts believe Zimmer Biomet Holdings is more attractive than Abbott Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZBH
    Zimmer Biomet Holdings
    6 16 1
    ABT
    Abbott Laboratories
    12 9 0
  • Is ZBH or ABT More Risky?

    Zimmer Biomet Holdings has a beta of 0.710, which suggesting that the stock is 28.957% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.731, suggesting its less volatile than the S&P 500 by 26.93%.

  • Which is a Better Dividend Stock ZBH or ABT?

    Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 1.02%. Abbott Laboratories offers a yield of 1.76% to investors and pays a quarterly dividend of $0.59 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZBH or ABT?

    Zimmer Biomet Holdings quarterly revenues are $1.9B, which are smaller than Abbott Laboratories quarterly revenues of $10.4B. Zimmer Biomet Holdings's net income of $182M is lower than Abbott Laboratories's net income of $1.3B. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.85x while Abbott Laboratories's PE ratio is 17.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.48x versus 5.44x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZBH
    Zimmer Biomet Holdings
    2.48x 20.85x $1.9B $182M
    ABT
    Abbott Laboratories
    5.44x 17.09x $10.4B $1.3B
  • Which has Higher Returns ZBH or EW?

    Edwards Lifesciences has a net margin of 9.53% compared to Zimmer Biomet Holdings's net margin of 25.34%. Zimmer Biomet Holdings's return on equity of 7.29% beat Edwards Lifesciences's return on equity of 46.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZBH
    Zimmer Biomet Holdings
    71.2% $0.91 $19.6B
    EW
    Edwards Lifesciences
    78.65% $0.61 $10.8B
  • What do Analysts Say About ZBH or EW?

    Zimmer Biomet Holdings has a consensus price target of $108.44, signalling upside risk potential of 15.09%. On the other hand Edwards Lifesciences has an analysts' consensus of $81.79 which suggests that it could grow by 7.42%. Given that Zimmer Biomet Holdings has higher upside potential than Edwards Lifesciences, analysts believe Zimmer Biomet Holdings is more attractive than Edwards Lifesciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZBH
    Zimmer Biomet Holdings
    6 16 1
    EW
    Edwards Lifesciences
    11 17 1
  • Is ZBH or EW More Risky?

    Zimmer Biomet Holdings has a beta of 0.710, which suggesting that the stock is 28.957% less volatile than S&P 500. In comparison Edwards Lifesciences has a beta of 1.108, suggesting its more volatile than the S&P 500 by 10.836%.

  • Which is a Better Dividend Stock ZBH or EW?

    Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 1.02%. Edwards Lifesciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Edwards Lifesciences pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZBH or EW?

    Zimmer Biomet Holdings quarterly revenues are $1.9B, which are larger than Edwards Lifesciences quarterly revenues of $1.4B. Zimmer Biomet Holdings's net income of $182M is lower than Edwards Lifesciences's net income of $358M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.85x while Edwards Lifesciences's PE ratio is 10.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.48x versus 8.18x for Edwards Lifesciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZBH
    Zimmer Biomet Holdings
    2.48x 20.85x $1.9B $182M
    EW
    Edwards Lifesciences
    8.18x 10.88x $1.4B $358M
  • Which has Higher Returns ZBH or STE?

    Steris PLC has a net margin of 9.53% compared to Zimmer Biomet Holdings's net margin of 9.84%. Zimmer Biomet Holdings's return on equity of 7.29% beat Steris PLC's return on equity of 9.5%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZBH
    Zimmer Biomet Holdings
    71.2% $0.91 $19.6B
    STE
    Steris PLC
    43.31% $1.48 $8.7B
  • What do Analysts Say About ZBH or STE?

    Zimmer Biomet Holdings has a consensus price target of $108.44, signalling upside risk potential of 15.09%. On the other hand Steris PLC has an analysts' consensus of $264.88 which suggests that it could grow by 16.37%. Given that Steris PLC has higher upside potential than Zimmer Biomet Holdings, analysts believe Steris PLC is more attractive than Zimmer Biomet Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZBH
    Zimmer Biomet Holdings
    6 16 1
    STE
    Steris PLC
    3 3 0
  • Is ZBH or STE More Risky?

    Zimmer Biomet Holdings has a beta of 0.710, which suggesting that the stock is 28.957% less volatile than S&P 500. In comparison Steris PLC has a beta of 0.923, suggesting its less volatile than the S&P 500 by 7.704%.

  • Which is a Better Dividend Stock ZBH or STE?

    Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 1.02%. Steris PLC offers a yield of 1% to investors and pays a quarterly dividend of $0.57 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Steris PLC pays out 35.77% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZBH or STE?

    Zimmer Biomet Holdings quarterly revenues are $1.9B, which are larger than Steris PLC quarterly revenues of $1.5B. Zimmer Biomet Holdings's net income of $182M is higher than Steris PLC's net income of $145.7M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.85x while Steris PLC's PE ratio is 36.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.48x versus 4.13x for Steris PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZBH
    Zimmer Biomet Holdings
    2.48x 20.85x $1.9B $182M
    STE
    Steris PLC
    4.13x 36.71x $1.5B $145.7M
  • Which has Higher Returns ZBH or SYK?

    Stryker has a net margin of 9.53% compared to Zimmer Biomet Holdings's net margin of 11.15%. Zimmer Biomet Holdings's return on equity of 7.29% beat Stryker's return on equity of 14.2%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZBH
    Zimmer Biomet Holdings
    71.2% $0.91 $19.6B
    SYK
    Stryker
    63.83% $1.69 $37.7B
  • What do Analysts Say About ZBH or SYK?

    Zimmer Biomet Holdings has a consensus price target of $108.44, signalling upside risk potential of 15.09%. On the other hand Stryker has an analysts' consensus of $422.71 which suggests that it could grow by 8.15%. Given that Zimmer Biomet Holdings has higher upside potential than Stryker, analysts believe Zimmer Biomet Holdings is more attractive than Stryker.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZBH
    Zimmer Biomet Holdings
    6 16 1
    SYK
    Stryker
    13 9 0
  • Is ZBH or SYK More Risky?

    Zimmer Biomet Holdings has a beta of 0.710, which suggesting that the stock is 28.957% less volatile than S&P 500. In comparison Stryker has a beta of 0.915, suggesting its less volatile than the S&P 500 by 8.528%.

  • Which is a Better Dividend Stock ZBH or SYK?

    Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 1.02%. Stryker offers a yield of 0.85% to investors and pays a quarterly dividend of $0.84 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZBH or SYK?

    Zimmer Biomet Holdings quarterly revenues are $1.9B, which are smaller than Stryker quarterly revenues of $5.9B. Zimmer Biomet Holdings's net income of $182M is lower than Stryker's net income of $654M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.85x while Stryker's PE ratio is 52.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.48x versus 6.50x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZBH
    Zimmer Biomet Holdings
    2.48x 20.85x $1.9B $182M
    SYK
    Stryker
    6.50x 52.82x $5.9B $654M
  • Which has Higher Returns ZBH or TMCI?

    Treace Medical Concepts has a net margin of 9.53% compared to Zimmer Biomet Holdings's net margin of -30.29%. Zimmer Biomet Holdings's return on equity of 7.29% beat Treace Medical Concepts's return on equity of -47.17%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZBH
    Zimmer Biomet Holdings
    71.2% $0.91 $19.6B
    TMCI
    Treace Medical Concepts
    79.69% -$0.25 $158.8M
  • What do Analysts Say About ZBH or TMCI?

    Zimmer Biomet Holdings has a consensus price target of $108.44, signalling upside risk potential of 15.09%. On the other hand Treace Medical Concepts has an analysts' consensus of $10.02 which suggests that it could grow by 71.23%. Given that Treace Medical Concepts has higher upside potential than Zimmer Biomet Holdings, analysts believe Treace Medical Concepts is more attractive than Zimmer Biomet Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZBH
    Zimmer Biomet Holdings
    6 16 1
    TMCI
    Treace Medical Concepts
    2 4 0
  • Is ZBH or TMCI More Risky?

    Zimmer Biomet Holdings has a beta of 0.710, which suggesting that the stock is 28.957% less volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ZBH or TMCI?

    Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 1.02%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZBH or TMCI?

    Zimmer Biomet Holdings quarterly revenues are $1.9B, which are larger than Treace Medical Concepts quarterly revenues of $52.6M. Zimmer Biomet Holdings's net income of $182M is higher than Treace Medical Concepts's net income of -$15.9M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.85x while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.48x versus 1.73x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZBH
    Zimmer Biomet Holdings
    2.48x 20.85x $1.9B $182M
    TMCI
    Treace Medical Concepts
    1.73x -- $52.6M -$15.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Can Levi Stock Double?
Can Levi Stock Double?

Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…

How High Can SharkNinja Stock Go?
How High Can SharkNinja Stock Go?

If you know popular consumer appliance brands Shark and Ninja,…

Stock Ideas

Buy
70
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
82
SBET alert for Jul 17

SharpLink Gaming [SBET] is down 3.08% over the past day.

Buy
89
EXOD alert for Jul 17

Exodus Movement [EXOD] is down 1.75% over the past day.

Sell
42
VLCN alert for Jul 17

Volcon [VLCN] is up 256.56% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock